Apyx Medical Corporation Joins Russell 3000® and Russell 2000® Indexes
July 01 2019 - 7:30AM
Business Wire
Apyx Medical Corporation, formerly Bovie Medical
Corporation, (NASDAQ:APYX) (the “Company”), a maker of
medical devices and supplies and the developer of J-Plasma®, a
patented surgical product marketed and sold under the Renuvion®
Cosmetic Technology brand in the cosmetic surgery market, announced
today that the Company has been added to the Russell 3000® and
Russell 2000® Indexes. The Company’s inclusion occurred as part of
the annual reconstitution by FTSE Russell of its U.S. equity
indexes and will become effective today after the U.S. market
opens.
“Apyx Medical is pleased to be included in the Russell 3000 and
2000 Indexes,” said Charlie Goodwin, President and Chief Executive
Officer. “These indexes are widely used by investment managers and
institutional investors, and we expect our inclusion in them to
enhance our company’s visibility in the public markets.”
Membership in the Russell 3000 Index is determined primarily by
objective, market-capitalization rankings and style attributes, and
remains in place for a minimum of one year. Membership in the
Russell 3000 Index results in automatic inclusion in either the
large-cap Russell 1000® Index or small-cap Russell 2000 Index. In
connection with membership in each Russell index, companies are
also included in the appropriate growth and value style
indexes.
About Apyx Medical
Corporation:
Apyx Medical Corporation (formerly Bovie Medical Corporation) is
an advanced energy technology company with a passion for elevating
people’s lives through innovative products in the cosmetic and
surgical markets. Known for its innovative Helium Plasma
Technology, Apyx is solely focused on bringing transformative
solutions to the physicians and patients it serves. The company’s
Helium Plasma Technology is marketed and sold as Renuvion® in the
cosmetic surgery market and J-Plasma® in the hospital surgical
market. Renuvion offers plastic surgeons, fascial plastic surgeons
and cosmetic physicians a unique ability to provide controlled heat
to the tissue to achieve their desired results. The J-Plasma system
allows surgeons to operate with a high level of precision and
virtually eliminating unintended tissue trauma. The Company also
leverages its deep expertise and decades of experience in unique
waveforms through original equipment manufacturing (OEM) agreements
with other medical device manufacturers. For further information
about the Company and its products, please refer to the Apyx
Medical Corporation website at www.ApyxMedical.com.
Cautionary Statement on Forward-Looking
Statements:
Certain matters discussed in this release and oral statements
made from time to time by representatives of the Company may
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and the Federal
securities laws. Although the Company believes that the
expectations reflected in such forward-looking statements are based
upon reasonable assumptions, it can give no assurance that its
expectations will be achieved.
Forward-looking information is subject to certain risks, trends
and uncertainties that could cause actual results to differ
materially from those projected. Many of these factors are beyond
the Company’s ability to control or predict. Important factors that
may cause actual results to differ materially and that could impact
the Company and the statements contained in this release can be
found in the Company’s filings with the Securities and Exchange
Commission including the Company’s Report on Form 10-K for the year
ended December 31, 2018 and subsequent Form 10-Q filings. For
forward-looking statements in this release, the Company claims the
protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
The Company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190701005075/en/
Investor Relations Contact:
Westwicke Partners on behalf of Apyx Medical Corporation Mike
Piccinino, CFA investor.relations@apyxmedical.com
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From Sep 2023 to Sep 2024